Strong 2025 performance with renewedcommercial momentum at year-endRevenue up +10.3% in constant currencies, led by +14.4% growth in constant currencies of Planisware’s SaaS Model Commercial momentum improving and strong bookings with new logos at year-end Adjusted EBITDA margin* up +220bps to 37.4% of revenue reflecting operational discipline and scalability Profit for the period up +17.0% year-on-year to € 50.0 million or € 0.71 earnings per share Strong cash generation with adjusted FCF* reaching € 59.3 million (80.1% cash conversion), reinforcing the sound net cash position* reaching € 195.6 million € 0.36 proposed dividend per share, +16.1% year-on-year, representing a 50% pay-out 2026 objectives:Low double-digit revenue growth in constant currencies c. 37% Adjusted EBITDA margin1 c. 80% Cash Conversion Rate*Paris, France,...

Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MGResults support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMGRegulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG). ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living...

Ad hoc announcement pursuant to Article 53 LR26 February 2026 – 06:30 AMThe Feintool Group’s business performance in the 2025 financial year reflects a market environment that remains challenging, with differing dynamics across regions and technologies. The global automotive market is growing at a low single-digit rate, while shifts in climate policy and subsidy schemes – particularly in the United States – are influencing investment decisions and the pace of electrification. At the same time, demand for industrial applications has remained subdued. Against this backdrop, Feintool has continued to align its cost structure consistently with prevailing market conditions, while maintaining a high degree of operational flexibility and a solid financial base. This enables the Group to remain a reliable and well-established partner for its customers,...

BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials. The Company completed patient enrollment of a Phase III registrational clinical trial of BCL2 inhibitor mesutoclax (ICP-248) in combination with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. Mesutoclax is a novel, highly selective oral BCL2 inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity...

New office strengthens global engineering capabilities to scale intelligent AI agents worldwide SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today announced the opening of its new state-of-the-art innovation hub in Bengaluru, India. The expansion marks a significant milestone in the company’s evolution to scale agentic AI globally, positioning SoundHound at the epicenter of India’s rapidly accelerating AI economy. The opening coincides with a period of historic momentum for the Indian technology sector. As the country reinforces its role as a global AI powerhouse, SoundHound’s new Bengaluru hub will serve as a critical engine for the company’s next wave of innovation, including continued advancement of its next generation agentic AI platform. SoundHound...

Saskatoon, SK., Feb. 25, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the pricing of a registered direct offering to purchase 7,150,000 common shares (or pre-funded warrants in lieu thereof) of the Company (each, a “Common Share” or “Pre-Funded Warrant”), at a price of US$7.00, for gross proceeds of approximately US$50.0 million, before deducting placement agent discounts and offering expenses (the “Offering”). Maxim Group LLC is acting as lead placement agent for the Offering. Raymond James Ltd. and Ladenburg Thalmann & Co. Inc. are acting as co-placement agents for the offering. Draganfly currently intends to use the net proceeds from the Offering for general corporate purposes,...

NEW YORK, NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) — TRG Latin America Acquisitions Corp. (“TRG” or the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Stock Exchange (“Nasdaq”) and trade under the ticker symbol “TRGSU” beginning February 26, 2026. Each unit consists of one Class A ordinary share and one right entitling the holder thereof to receive one-tenth of one Class A ordinary share upon the consummation of an initial business combination. The Class A ordinary shares and rights comprising the units are expected to begin separate trading no later than the 52nd day following this date. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under...